

**Analytical Profiles
of
Drug Substances**

Volume 10

Edited by
Klaus Florey

Analytical Profiles of Drug Substances

Volume 10

Edited by

Klaus Florey

*The Squibb Institute for Medical Research
New Brunswick, New Jersey*

Contributing Editors

Rafik Bishara	Lee T. Grady
Glenn A. Brewer, Jr.	Hans-Georg Leemann
John E. Fairbrother	Joseph A. Mollica

Bruce C. Rudy

*Compiled under the auspices of the
Pharmaceutical Analysis and Control Section
Academy of Pharmaceutical Sciences*



ACADEMIC PRESS 1981

**A Subsidiary of Harcourt Brace Jovanovich, Publishers
New York London Sydney Toronto San Francisco**

COPYRIGHT © 1981, BY ACADEMIC PRESS, INC.
ALL RIGHTS RESERVED.
NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR
TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC
OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR ANY
INFORMATION STORAGE AND RETRIEVAL SYSTEM, WITHOUT
PERMISSION IN WRITING FROM THE PUBLISHER.

ACADEMIC PRESS, INC.
111 Fifth Avenue, New York, New York 10003

United Kingdom Edition published by
ACADEMIC PRESS, INC. (LONDON) LTD.
24/28 Oval Road, London NW1 7DX

Library of Congress Cataloging in Publication Data
Main entry under title:

Analytical profiles of drug substances.

Compiled under the auspices of the Pharmaceutical
Analysis and Control Section. Academy of Pharmaceutical
Sciences.

Includes bibliographical references and index.
I. Drugs--Analysis--Collected works. 2. Chemistry,
Pharmaceutical--Collected works. I. Florey, Klaus.
II. Brewer, Glenn A. III. Academy of Pharmaceutical
Sciences. Pharmaceutical Analysis and Control Section.
[DNLM: 1. Drugs--Analysis--Yearbooks. QV740 A41 A55]
RS189.A58 615'.1 70-187259
ISBN 0-12-260810-0 (v. 10) AACR1

PRINTED IN THE UNITED STATES OF AMERICA

81 82 83 84 9 8 7 6 5 4 3 2 1

AFFILIATIONS OF EDITORS, CONTRIBUTORS, AND REVIEWERS

- H. Y. Aboul-Enein*, Riyadh University, Riyadh, Saudi Arabia
A. A. Al-Badr, Riyadh University, Riyadh, Saudi Arabia
N. W. Atwater, E. R. Squibb and Sons, Princeton, New Jersey
S. A. Benezra, Burroughs Wellcome Company, Research Triangle Park,
North Carolina
W. F. Beyer, The Upjohn Company, Kalamazoo, Michigan
R. Bishara, Eli Lilly and Company, Indianapolis, Indiana
J. I. Bodin, Carter Wallace, Inc., Cranbury, New Jersey
G. A. Brewer, The Squibb Institute for Medical Research,
New Brunswick, New Jersey
H. Brik, Gist-Brocades, Delft, Holland
L. W. Brown, The Upjohn Company, Kalamazoo, Michigan
L. Chafetz, Warner-Lambert Research Institute, Morris Plains,
New Jersey
C. C. Chiu, The United States Pharmacopeia, Rockville, Maryland
H. P. Deppeler, Ciba-Geigy Ltd., Basel, Switzerland
H. A. El-Obeid, Riyadh University, Riyadh, Saudi Arabia
J. Fairbrother, Stiefel Laboratories Ltd., Sligo, Ireland
L. V. Feyns, The United States Pharmacopeia, Rockville, Maryland
K. Florey, The Squibb Institute for Medical Research, New Brunswick,
New Jersey
P. R. B. Foss, Burroughs Wellcome Company, Research Triangle Park,
North Carolina
S. A. Fusari, Parke-Davis, Inc., Detroit, Michigan
L. T. Grady, The United States Pharmacopeia, Rockville, Maryland
M. M. A. Hassan, Riyadh University, Riyadh, Saudi Arabia
S. E. Ibrahim, Riyadh University, Riyadh, Saudi Arabia
A. I. Jado, Riyadh University, Riyadh, Saudi Arabia

- T. Kho*, Ayerst Laboratories, Rouses Point, New York
J. Kirschbaum, The Squibb Institute for Medical Research,
New Brunswick, New Jersey
K. Krummen, Sandoz, Basel, Switzerland
H. G. Leemann, Sandoz, Basel, Switzerland
G. G. Liversidge, University of Nottingham, Nottingham, England
M. A. Loutfy, Riyadh University, Riyadh, Saudi Arabia
F. Maxl, Sandoz, Basel, Switzerland
J. Mollica, Ciba-Geigy Corporation, Suffern, New York
J. S. Mossa, Riyadh University, Riyadh, Saudi Arabia
F. J. Muhtadi, Riyadh University, Riyadh, Saudi Arabia
F. Nachtmann, Sandoz, Basel, Switzerland
G. R. Padmanabhan, Ciba-Geigy Ltd., Suffern, New York
G. Papariello, Wyeth Laboratories, Philadelphia, Pennsylvania
E. Riemer, Sandoz, Basel, Switzerland
B. C. Rudy, Mary Kay Cosmetics, Dallas, Texas
R. W. Souter, Eli Lilly, Indianapolis, Indiana
S. Sun, The United States Pharmacopeia, Rockville, Maryland
P. G. Takla, University of Wales Institute of Science and Technology,
South Wales, United Kingdom
W. P. Wilson, Burroughs Wellcome Company, Research Triangle Park,
North Carolina
D. K. Wyatt, The United States Pharmacopeia, Rockville, Maryland
M. D. Yudis, Schering-Plough, Inc., Bloomfield, New Jersey
M. U. Zubair, Riyadh University, Riyadh, Saudi Arabia

PREFACE

Although the official compendia list tests and limits for drug substances related to identity, purity, and strength, they normally do not provide other physical or chemical data, nor do they list methods of synthesis or pathways of physical or biological degradation and metabolism. For drug substances important enough to be accorded monographs in the official compendia, such supplemental information should also be made readily available. To this end the Pharmaceutical Analysis and Control Section, Academy of Pharmaceutical Sciences, has undertaken a cooperative venture to compile and publish *Analytical Profiles of Drug Substances* in a series of volumes of which this is the tenth.

The concept of analytical profiles is taking hold not only for compendial drugs but, increasingly, in the industrial research laboratories. Analytical profiles are being prepared and periodically updated to provide physiochemical and analytical information of new drug substances during the consecutive stages of research and development. Hopefully, then, in the not-too-distant future, the publication of an analytical profile will require a minimum of effort whenever a new drug substance is selected for compendial status.

The cooperative spirit of our contributors has made this venture possible. It is gratifying to note that increasingly profiles are being written not only in industrial laboratories but also in academic institutions worldwide.

All those who have found the profiles useful are requested to contribute a monograph of their own. The editors stand ready to receive such contributions.

The goal to cover all drug substances with comprehensive monographs is still a distant one. It is up to our perseverance to make it a reality.

Klaus Florey

CONTENTS

<i>Affiliations of Editors, Contributors, and Reviewers</i>	ix
<i>Preface</i>	xi
Aminosalicyclic Acid	1
<i>Mahmoud M. A. Hassan, Ahmad I. Jado, and Muhammad Uppal Zubair</i>	
Azathioprine	29
<i>Wendy P. Wilson and Steven A. Benezra</i>	
Benzyl Benzoate	55
<i>Mahmoud M. A. Hassan and Jaber S. Mossa</i>	
Clindamycin Hydrochloride	75
<i>Leo W. Brown and William F. Beyer</i>	
Codeine Phosphate	93
<i>Farid J. Muhtadi and Mahmoud M. A. Hassan</i>	
Colchicine	139
<i>Dorothy K. Wyatt, Lee T. Grady, and Sy-rong Sun</i>	
Cyanocobalamin	183
<i>Joel Kirschbaum</i>	
Emetine Hydrochloride	289
<i>L. Valentin Feyns and Lee T. Grady</i>	
Glibenclamide	337
<i>Pamela Girgis Takla</i>	

Heroin	357
<i>Dorothy K. Wyatt and Lee T. Grady</i>	
Hydrochlorothiazide	405
<i>Hans Peter Deppeler</i>	
Ketoprofen	443
<i>Gary G. Liversidge</i>	
Methylphenidate Hydrochloride	473
<i>Gandharva R. Padmanabhan</i>	
Nabilone	499
<i>Rex W. Souter</i>	
Natamycin	513
<i>Harry Brik</i>	
Oxytocin	563
<i>Friedrich Nachtmann, Kurt Krummen, Friedrich Maxl, and Erich Riemer</i>	
Penicillamine	601
<i>Ching Ching Chiu and Lee T. Grady</i>	
Probenecid	639
<i>Abdullah A. Al-Badr and H. A. El-Obeid</i>	
Salbutamol	665
<i>Hassan Y. Aboul-Enein, Abdullah A. Al-Badr, and S. E. Ibrahim</i>	
Succinylcholine Chloride	691
<i>Penelope R. B. Foss and Steven A. Benezra</i>	
Trioxsalen	705
<i>Mahmoud M. A. Hassan and Mohammed A. Loutfy</i>	
ERRATA FOR VOLUME 9	
Cefamandole Nafate	729
<i>Rafik H. Bishara and Eugene C. Rickard</i>	

CONTENTS

vii

Fluphenazine Decanoate <i>Geoffrey Clarke</i>	730
Gentamicin Sulfate <i>Bernard E. Rosenkrantz, Joseph R. Greco, John G. Hoogerheide, and Edwin M. Oden</i>	731
Nadolol <i>Lidia Slusarek and Klaus Florey</i>	732
<i>Cumulative Index</i>	733

AMINOSALICYLIC ACID

*Mahmoud M. A. Hassan, Ahmad I. Jado,
and Muhammad Uppal Zubair*

1. Description	2
1.1 Nomenclature	2
1.2 Formulae	2
1.3 Molecular Weight	3
1.4 Elemental Composition	3
1.5 Appearance, Color, Taste, Odor	3
2. Physical Properties	3
2.1 Crystal Properties	3
2.2 Solubility	6
2.3 Identification	7
2.4 Spectral Properties	7
3. Synthesis	17
4. Metabolism	19
5. Methods of Analysis	21
5.1 Nonaqueous Titration	21
5.2 Diazometric Assay	22
5.3 Spectrophotometry	23
5.4 Combined TLC and Colorimetry	23
5.5 Ultraviolet Method	23
References	25

1. DESCRIPTION

1.1 Nomenclature

1.1.1 Chemical Names

- a. 4-Amino-2-hydroxybenzoic acid.
- b. 4-Aminosalicylic acid.
- c. Benzoic acid, 4-Amino-2-hydroxy.

The CAS Registry No. is [65-49-6].

1.1.2 Generic Name


p-Aminosalicylic acid.

1.1.3 Trade Names


Apas, Apacil, Deapasil, Hellipidyl, PAS, . PAS-C, Pamcyl, Pamisyl, Parasil, Pasorbic, Pasolac, Parasalicil, Parasalindon, Pasnodia, Propasa, Rezipas, Sanipirrol-4, Para-Pas, Pasem.

1.2 Formulae

1.2.1 Empirical



1.2.2 Structural



1.2.3 Wiswesser Line Notation

ZR CQ DVQ

1.3 Molecular Weight

153.13

1.4 Elemental Composition

C, 54.90%; H, 4.61%; N, 9.5%; O, 31.34%.

1.5 Appearance, Color, Taste, Odor

White, or yellowish white, bulky powder or crystals darkens on exposure to light and air, odorless or has slight acetous odor.

2. Physical Properties

2.1 Crystal Properties

2.1.1 X-Ray Diffraction

Crystal data

Monoclinic, $a = 7.209$ (2), $b = 3.786$ (1), $c = 25.109$ (9) Å, $B = 103.22$ (3)°, $U = 6.67.14$ Å³, $Z = 4$, $D_c = 1.53$, $F(000) = 320$. Cu-K α radiation, $\lambda = 1.5418$ Å; μ (Cu-K α) = 10.20 cm⁻¹. Systematic absences = $h0l$, $l = 2n + 1$, $0k0$, $k = 2n + 1$, space group $P2_1/C$ from systematic absences (1).

Optical goniometry

It crystallises from ethanol in at least two habits. The interfacial angles of habit I were measured with a Huber two circle optical goniometer and compared with angles calculated from unit-cell dimensions for all faces having Miller indices between (and including) +2 and -2. A unique set of assignments for the faces was obtained and confirmed by precision photography. The $h k o$ net was in approximately reflecting position on the precession camera when the face-assigned indices (001) were approximately normal to X-ray beam. Fig. 1 shows a schematic drawing of habit I with assigned faces. The end faces of habit II did not have the indices (011) but precession photography and optical goniometry showed that (001) and (102) were its two largest faces.






Fig. 1 : Schematic diagram of crystals of p-Aminosalicylic acid in habit I.

Crystal Structure

Two different crystal structures have been reported for p-aminosalicylic acid. Structure II has been reported before the advent of modern computers (2) while structure I has been developed very recently (1). Table 1 and 2 list the bond lengths and angles and Table 3 atom positions. Intramolecular contacts and angles involving the $O(1)-H(21)\dots O(2)$ hydrogen bond are also included. Data for p-aminosalicylic acid are consistent with the idea that resonance structure (Ib) and (Ic) contribute significantly to its structure.



I



II




Table 1

Bond lengths (Å) in p-aminosalicylic acid (1), with standard deviations in parentheses. Intramolecular contacts involving the O(1)-H(21)...O(2) hydrogen bond are included.

O(1)-C(2)	1.361(2)	C(1)-C(2)	1.414(2)
O(2)-C(7)	1.243(2)	C(1)-C(6)	1.400(3)
O(3)-C(7)	1.311(2)	C(1)-C(7)	1.447(2)
O(2)...O(1)	2.620(2)	C(2)-C(3)	1.371(2)
N(1)-C(4)	1.364(2)	C(3)-C(4)	1.392(3)
O(1)-H(21)	0.98(3)	C(4)-C(5)	1.406(3)
O(3)-H(71)	0.95(3)	C(5)-C(6)	1.362(2)
O(2)...H(21)	1.73(3)	C(3)-H(3)	0.98(2)
N-H(41)	0.91(3)	C(5)-H(5)	0.98(2)
N-H(42)	0.83(3)	C(6)-H(6)	0.94(2)

Table 2

Bond angles(°) in p-aminosalicylic acid (1), with estimated standard deviations in parentheses. Angles involving the O(1)-H(21)...O(2) hydrogen bond are included.

O(2)-C(7)-O(3)	121.1(1)	O(1)-C(2)-C(3)	118.2(2)
O(2)-C(7)-C(1)	123(2)	C(2)-C(3)-C(4)	121.1(2)
O(3)-C(7)-C(1)	115.8(2)	C(3)-C(4)-C(5)	118.7(1)
C(7)-C(1)-C(2)	120.8(2)	C(3)-C(4)-N(1)	120.7(2)
C(7)-C(1)-C(6)	121.7(2)	C(5)-C(4)-N(1)	120.6(2)
C(2)-C(1)-C(6)	117.4(1)	C(6)-C(5)-C(4)	120.1(2)
C(1)-C(2)-O(1)	121.3(1)	C(1)-C(6)-C(5)	122.0(2)
C(1)-C(2)-C(3)	120.6(2)		
H(71)-O(3)-C(7)	113(2)	H(41)-N(1)-C(4)	120(2)
H(21)-O(1)-C(2)	107(2)	H(42)-N(1)-C(4)	115(2)
O(2)...H(21)-O(1)	147(3)	H(5)-C(5)-C(4)	119(1)
C(7)-O(2)...H(21)	100(1)	H(5)-C(5)-C(6)	121(1)
H(3)-C(3)-C(2)	118(1)	H(6)-C(6)-C(1)	119(1)
H(3)-C(3)-C(4)	121(1)	H(6)-C(6)-C(5)	119(1)
H(41)-N(1)-H(42)			

Table 3

Final atomic positions ($\times 10^4$; for H $\times 10^3$) for p-aminosalicylic acid (I), with standard deviations in parentheses.

	x	y	z
O(1)	6 882(2)	3 539(4)	1 641.0(5)
O(2)	5 572(2)	1 178(4)	651.0(5)
O(3)	7 438(2)	1 345(4)	58.2(5)
N(1)	13 290(3)	7 453(5)	2 111.6(8)
C(1)	8 718(2)	3 353(5)	946.6(6)
C(2)	8 539(2)	4 138(5)	1 483.1(6)
C(3)	10 041(3)	5 531(5)	1 860.5(7)
C(4)	11 784(2)	6 175(5)	1 728.6(7)
C(5)	11 966(3)	5 457(5)	1 193.8(7)
C(6)	10 474(2)	4 058(5)	819.9(7)
C(7)	7 136(2)	1 880(5)	547.1(6)
H(21)	601(4)	241(9)	133(1)
H(71)	637(4)	37(8)	-19(1)
H(41)	1 316(4)	789(8)	246(1)
H(42)	1 427(4)	782(8)	200(1)
H(3)	958(3)	602(6)	223(1)
H(5)	1 319(3)	595(6)	110(1)
H(6)	1 064(2)	354(5)	47(1)

2.1 2 Melting Range

The melting point of 4-aminosalicylic acid is uncertain (3) : 135°-140° with decomposition (4), 148° (dec.)(5), 149-151°(dec.)(6). 150-151° with effervescence (7,8), 139-141°(dec.) (9) and 220° (dec.)(10,11) have been reported. Seaman *et al* (3) have concluded that the most nearly correct melting point is about 240° and the melting point is not a good criterion of purity.

2.2 Solubility

1 g in about 600 ml of water and about 21 ml of alcohol; slightly soluble in ether; practically insoluble in benzene. Solubility is increased with alkaline salts of alkali metals (NaHCO_3) and in weak nitric acid, the amine salts of hydrochloric and sulphuric acids are insoluble. The aqueous solutions have a pH of about 3.2 and when heated the acid decomposes (12).

2.3 Identification

1. p-Aminosalicylic acid gives an intense orange-brown color when reacted with potassium ferricyanide in alkaline solution (13).
2. It gives a green color which changes first to orange and then to orange-red on reaction with hexamine and sulphuric acid at room temperature (14).

2.4 Spectral Properties

2.4 1 Infrared Spectrum

The infrared spectrum of 4-aminosalicylic acid is recorded as a nujol mull on Unicam SP 1025 Spectrophotometer and is shown in Fig. 2. The assignments for the characteristic bands in the infrared spectrum listed in Table 4.

Table 4

<u>Frequency cm⁻¹</u>	<u>Assignment</u>
3520	NH ₂
3400	NH ₂ , OH
1630	bonded C = O
890	isolated C-H out of plane deformation.
820	C-H out of plane deformation.
800	
770	

Other characteristic finger print bands are:

1305, 1230, 1200, 1170, 1110, 970, 725 and 690 cm⁻¹. Other values for PAS in potassium bromide disc (15) are, 3571, 3448, 3030, 1667, 1613, 1515, 1449, 1299, 1220, 1190, 1163, 813 and 775.

2.4 2 Ultraviolet Spectrum (UV)

UV spectrum of PAS in ethanol was scanned using Cary, 219 spectrophotometer ; from 400 to 200 nm(16), three maxima and two minima were observed. The maxima are located at 235, 274 and 303 nm.




Fig. 2 : Infrared Spectrum of p-Aminosalicylic acid in Nujol.